>> so far, kellykelly, about a hundred. >> wow. >> we had a tremendous last three days of business because of this promotion. we'll hope to get hundreds more. the whole idea is to make customers happy. it's a great way to become topical. people talk about this all over town. >> that's it for us on "closing be bell". >> this is "fast money." lots of big news in the bio tech space today. we are taking you to the jp morgan health care conference with the ceo of johnson and johnson. it's not just crude that's shaking things up.

tech stocks all closing in the red as we prepare to kick off earning season. >> we talked last week about how we wanted to sit it out and wait. i think when you're looking at it now we've got to see some of that volume return back to the marketplace. today was the lowest option day so far in 2015. >> really? >> we're seeing that volatility come out of the oil a little bit. but come right back in today because of this 5% move. the ovx, something to keep an eye on. we're push right back up there again. as i've said before, if oil is making significant moves, i don't know how the market can't react to that. on days like today, i think you have to be hands-off. this is the place we are finding the market. it's graph tavitating to around.

it's amazing to me how we stare down the barrel of earnings. commodity prices are at their lows. we see a number of valuation that is look stretched especially when you compare the u.s. to prices around the world. to think that this isn't a time where you could actually see the u.s. under perform other markets in world, i think this is something people should be looking at because this is exactly where we're headed in the next couple of weeks. >> obviously i think the oil move is incredibly destabilizing. the quality manifests itself in the bond market, which flattens the yield curve. i think will will be opportunities in banks. but pete's point, probably not yet. i think technically in the s&p 1956, 1960-ish -- that's not

cataclysmic. that's a 3% move. >> people might want to take a look at the financials and take a look at a . 8% decline. we are setting up for a very big week for earnings for banks. >> i'm holding all three of the big ones that i own, jp morgan, citibank and bank of america. these stocks having sold off fairly sharply, clearly with rates here at 1.9 on the ten-year, that's not great. they have faced this flat yield curve, though, for quite some time. so i'm staying in these banks. i think wednesday we'll get our first look. i think the valuation here is not -- hardly stretched at all. >> really interesting, i think if there's one sector that has

the ability to -- if you look at where we are levels from markets, the nasdaq is now below the 200 move day. there's been two other times this year where it's been below the 200 moving day. if you think this is a time where people are giving up momentum, there's more downside for the nasdaq here. >> apple is down 2.5%. >> how about intel, how about sysco? i saw western digital coming off highs and it was down today. i'm can karewith karen, though. i like these financials. these financials could potentially surprise a lot of people. >> let's talk oil here.

56 dollars a barrel today. trying to buy oil is like trying to catch a falling chain saw, not just a knife at this point. what's the downside risk to your lowered target? >> we're not really attached to anything. what we saw last time we were this low is the thing that sold the market was a 4 million barium cut by owe pepeck. we really don't know how long it's going to take for the market to fundamentally balance, other than it should be okay by the end of the year. crude demand is set to fall here and should be pretty ugly for prices for several months. >> and you think there could be bankruptcies. what kind of consolidations should we expect to see? >> we changed our methodology on how we name our long-term oil

price. when we need the oil, u.s. unconventional will start growing again. that's around $75 a barrel. the conclusion is that the saudi is really stuck here strategically. this is the place where we're going to balance the market, the u.s., and this will be a consolidation play. eagle foot, we expect all these places to consolidate and become bigger. >> to me it's extraordinarily destabilizing. crude is cut in half, more so now in the last six months. it's not a healthy move. do you factor geo political risk in any of the estimates that you make? >> the u.s. has been the price setter. economics is going to start setting the price, not politics. further to your destabilizing point, oil and gas is now 33% of

s&p 500. so there's an enormous underlying issue here with how the cuts we're seeing, 25 to 50% cuts now, how destabilizing that's going to be. we agree with you, absolutely. >> in terms of your picks, can you recommend these picks regardless of what the fundamentals are? >> the near term price is falling and falling. the back price is falling but anything like as fast. we're looking to hang onto that long-term 75-80 that we're talking about. we're buying quality for balance street sheets. so we're looking at stuff that could survive this environment, like hess. to catch the rubbish trade, you have to be exactly right on when

this all turns. and we don't know over the next six months exactly where this turn is coming. there's just too much oil right now. >> are these also the potential acquirers? >> what we're looking for if you want to buy the consolidation victims, if you want, would be smaller. they'd be the under 500 billion dollar market names. >> thank you. where do you go picking in the oil space, if at all? >> so far i've been hands off. >> completely? >> completely. i think it is supply. i do think there's a little bit of the demand story. i think these speckulators are really a bigger part of this than everybody wants to give them credit for. when you're getting 4 and 5% moves in a single day, to me

that's speckulators. >> we talked about the tanker space which has actually been the beneficiary of the worm being awash in oil. it's had a huge run, but i think investors should be aware that front line has a big bond offering that's maturing in april. what they've done, though, is swap equity for bond a lot of times. so it wouldn't be shocking to see an equity offering, some sword sort of secondary or swap. >> are you still in it? >> i'm still in it. i just think it's had a huge run and i could see that offering any day. >> first of all, in terms of the defense of hey they're going away, the end of the oil age,

conico. the refiners, basically saying too much crude equals too much product. and refiners have been very very defensive. >> the spread has collapsed. >> it's not going to give these guy what is they need. that's a place that you could get on the short side. >> after hours trading up about 1% after the aluminum responded better -- and ceo klekre ceo tel ra -- excel rated transformation. and a two to four % rise in auto production. and this is one of my favorite charts of the day. so if you're wonding how it's

performed since exiting the dough industrials. take a look at this chart. shares have nearly doubled versus the dow's 17% game. this is another quarter where we're seeing more of this rebound story playing out with alcoa. >> i thought it was really impressive when an analyst came out and was talking about this in such a bullish way. $23 target, talked about some of the profitability, some of the margins. >> hasn't that been priced in? >> no. >> it's trading 20% expensive to its peers. you have a place where aluminum prices are trapped. that's still a big part of their business. >> you captured the pop, right? so now what do you do. >> i think it's going 17. this analyst is saying that's his 12-month target. i look at this company and we see the growth going on in

aerospace and automotives. i think there's good tail winds right now. >> a black eye for the little blue box, tiffany getting hammered on the back of earnings.

. . breaking news out of d.c. >> 48-year-old banker antonio weiss has taken his name out of consideration to be the treasure department's under secretary of finance. that means he's going to take a new position as counselor to secretary jack lou. and he wouldn't face any confirmation battle. there's some question whether he could get through a confirmation. antonio weiss now not going to be the under secretary of domestic finance, but will in fact will a counselor to jack lou. >> thank you very much. a multibillion dollar deal

in gbio tech. let's get to meg. >> meg, thank you so much. this news came out before the conference even began. some of the biggest deal news. >> thanks for having me. >> let's get right video into this deal. some of the biggest news of the conference. there is a drug decision expected at the fda in a couple of weeks. tell us about the decision now. >> the proposed acquisition is right on strategy. we have done a very thorough diligence. relooked e e ed -- we looked at advisory committee.

the earlier you get in typically the better is the launch. >> and we saw the stock decline a little bit today although analysts seemed very supportive of the deal. >> a recent study showed that the best m and a is done also in aerospace by people that know their area very well. it's an area where they have sector dominance. we are a bio technology company focused on rare diseases and we know gi very well. we're very confident this will pay off. this deal will add to our growth. it has two unencumbered global rights. it will have an impact already

in 2016. so we feel very confident that we know how to make such deals and the deal would be very positive mid to long-term. we also january 2014 made a great aquisition of a company and there we showed in a very short peesriod of time we could show revenue. and i think that paid off very well. >> as you're growing in rare diseases, i think a lot of people expect you could see more acquisition. >> of course, we constantly are have our eyes on other opportunities. now we want to bring in one over the finishing line. i think it's a great deal. i think when we do a deal, we focus on quick integration to capture the si the synenergies.

we have enough capacity to add to our growth and our bio technology focus in rare diseases and consolidate our leadership in that space. >> one of the biggest pressures on drug industry evaluations now is drug pricing. a lot of people say you're insulates from that. do you feel like drug prices are sustainable where they are or are you guys going to feel that same pressure yes, ma'am. >> >> the best way to show value is to bring invasion to the marketplace. 40% of those were in the rare disease space. so i think we're in a good space and i think we have to continue to bring innovation and show the value of our medicines. and the deal is bringing two

truly innovative products to market, one already approved in three markets, another one soon to be approved in at least one mak market, the largest in the world. >> thank you so much for joining us. >> thanks for having me. >> back to you. >> we'll join meg a little bit later on because we'll hear from the ceo of johnson and johnson live. take a look at just the surface. it doesn't look like bio tech has made a lot of moves. but under surface, enormous, enormous moves. >> there are or names. that he is

that's had a nice move. agio. their secondary their priced at 110.75, i think. that stock is still preti ipret sbrets -- interesting. >> we did sell some a couple of weeks ago when we got a little spooked about the pricing. we bought some fbt, which is a smaller bio tech etf. the companies within it are smaller as well. this merger party doesn't seem to be ready to die down any time soon. >> fbt is the first trust just in case you're wondering. coming up next, tiffany shares seeing their worst day in ten years. what it means for the rest of the high end retail trade.

. take a look at wolverine world wide. the stock is falling about 3%. >> a big day for retail and two very different stories from tiffany and lululemon. worst day in 12 years for tiffany over the holiday season.

lululemon the exact opposite, strong holiday sales. >> we see what happens, you get that positive momentum. tiffany, it was disappointing not just this quarter. the guidance for next year was clearly lower than people thought, both revenue and eps. and a lot of the air in the multiple just came out of the name. i am surprised how drastic the sell-off was today. this is a great name still. it's expensive but i think there's an element of the holder base that feels the story or the ride is over here and i want to get out and that's it. >> don't they have a credibility problem? they reaffirmed their quarter in late november. they didn't have handle on the quarter. so how do they have a handle on 2015? >> how often did they correct the earnings outlook? that to me is not a big deal,

especially with all the macro forces out there. things could have happened on the currency side. these guys are the number one play you want to go after. it's now trading at 20 times 2015. that puts it right back where it's supposed to be. i don't know that you have to buy this thing tomorrow, but you get this thing on your radar screen if you're waiting for a pull-back. >> how about lululemon? >> i love that name. it was too cheap. they had the growth. they started to actually get this whole thing turned around. they've turned it around to the point where i do think it's expensive. >> it's up 60% after three months. >> this is a case of a company that people thought was absolutely broken. so they took it down to 40 bucks. it's gone from 40 to 65.

not cheap. >> the company said it expects revenue to fall short based on softer sales of storage for its mobile devices. >> i feel like this one, over reaction to the downside. this was well over 100. got down to $82 today. i think now is probably an opportunity. you still need to wait a couple of days. a lot of times when you get these big sells, i don't think you want to buy that day or the next day. but i think sometime next week i'm going to be in san disk. >> we traded down to levels we last saw in october. i think it made a low of $2. boun -- $82.

bounce add little bi bounced a little bit, not that much. 82 or above i think is a buy. >> and makes them in the enterprise space that much more of a heft. i think that's great as well. >> the chevy bolt is challenging tesla. should tesla be worried? that's ahead. tdd# 1-800-345-2550 [ male announcer ] your love for trading never stops, tdd# 1-800-345-2550 even on the go. tdd# 1-800-345-2550 open a schwab account, and you could earn tdd# 1-800-345-2550 300 commission-free online trades. tdd# 1-800-345-2550 so when a market move affects one of your positions, tdd# 1-800-345-2550 schwab can help you decide what to do. tdd# 1-800-345-2550 with tools like free live-streaming cnbc tv tdd# 1-800-345-2550 that give you the latest financial news and trends. tdd# 1-800-345-2550 and bubble charts and price charts that let you see exactly tdd# 1-800-345-2550 how market activity is affecting your positions. tdd# 1-800-345-2550 so when the time comes to decide whether to scale in

tdd# 1-800-345-2550 or scale out you can make your move, tdd# 1-800-345-2550 wherever you are. tdd# 1-800-345-2550 and start working on your next big idea. tdd# 1-800-345-2550 ♪ open a schwab account and you could earn tdd# 1-800-345-2550 300 commission-free online trades. tdd# 1-800-345-2550 tdd# 1-800-345-2550 call 1-877-729-2379. tdd# 1-800-345-2550 or visit schwab.com/trading. tdd# 1-800-345-2550 schwab trading services. tdd# 1-800-345-2550 your go-to for trading know-how. tdd# 1-800-345-2550 ♪

tdd# 1-800-345-2550 your go-to for trading know-how. toothbrush... sweater... extra sweater... headphones, sleeping mask... oh, and this is the xfinity tv app. he can watch his dvr'd shows from where ever he wants. hey. have fun, make some friends. alright. did i mention his neck pillow? (sniffs pillow) watch your personal dvr library where ever you go. with the x1 entertainment operating system.

. zbliel ahead >> still ahead on fa"fast money the ceo of johnson and johnson joins us live with somewhatwhat store for 2015. later as crude falls farther we've got the one oil services play that could get crushed this year. we're naming names. tesla shares getting hit today as the chevy bolt could be a

competitor to tesla's model three in range and price point. while this may be a minor set back for tesla stock, no other auto maker will be able to compete in the long run. should they be worried? not only is it competing on price point, on distance driven in a single charge but gm is going to have an advantage in this distribution network. >> so far what we've seen from gm has been pretty lacquekluste performance with the volt. we don't expect anything different. if you had a chance to look at the concept car today, lackluster is a great word to describe it. i don't think tesla would produce anything of the sort of a car like that. >> gm doesn't have to win this game. it just has to take incremental units away from tesla. is that a risk in your model at

all? >> the way that we've always looked at it is that tesla is a performance car and a luxury car manufacturer. and we expect the model three will compete with the audi a4. you won't have the same performance characteristics. >> you do think there will be competition in the space. i think bmw is going to be a major competitor? is this really the place that you get excited about everything that you're doing? i think they should be excited about it. >> well there's a couple thing there is. one, it would be good to see tesla as not a niche player. if we get -- i think that helps

with over all valuation for tesla. i do think as companies cross poll ennate on charging -- the more the better out there as far as ev's go. but tesla still has the lead here i think on the technology front. >> you've got a market performer rating on the stock. just in the past year to date the stock is down 10%. it has not been trading well. and a lot of people say it's because of oil and the decline we've seen in oil. we've had a number of banks slash their oil forecasts. is tesla the kind of trade you can be in and be comfortable with a market rating where oil this year may only go up to 70 bucks a barrel? >> oil has definitely been a pressure on the stock. the quarter has had some

weakness in it. and lots of people think they're going to miss their delivery. the sentiment is probably the worst i've ever seen it since covering the stock. to me that's a bullish indicator here. >> thanks for your time. >> thanks. >> it has traded textbook technically now for a while, on the way down 220. if it breaches we'll trade below 200. it did. we tested that 220 level. here we are now. i think the stock has a 180 handle on it. maybe if it gets down there, that's a good time to buy some. >> i think that's a good time to buy. >> i disagree a little bit with ben. i would say the sentiment has never been this low. but it was absurdly high. it was at a place that was

unsustainable. to say that people are betting against it, i think you'd be crazy to be betting against the stock too much higher here. >> when you mentioned something being absurdly high, this was just back in september -- the stocks in september to its recent low in december is down 34%. >> pretty significant hit to the downside. we tried to help people out by saying look volatility options is cheap. you can only be involved in this stock from the long end if you're in calls or call spreads. that has completely changed. volatility has changed. >> it's a no-touch for you? >> it's a no-touch, yeah. >> you could be having a similar conferring talking about a stock which is very interesting technolo technology. does have a lot of competition, however. 53 is the next level on the

stock in my view. >> pandora. >> it bounced 4%. but every rally in the stock has been a sell. 46 years ago today zeppelin released -- >> 46 years ago today. go on. >> nice. >> glad to now that. twitter down. >> the military hacking certainly didn't held the stock today. and the took has been on an incredible run since december 31st, up 12%. i don't think it's time to short it. i think the stock seems to have bottomed. >> cullen/frost. >> going a while back, i think they talked about expose your still being okay with oil at 50 or higher. now that it's broken 50, i think they'll probably get a little nervous, not that i think

disaster is coming but the valuation here seems a little bit high. >> and the drop for psycho selfies. men who post selfies on social media are more likely to exhibit psychopathic traits. the study found that chronic selfie takers scored higher on measures of narcissism and psycho pathy. the biggest narcissists were the ones who spent extra time editing their selfies. >> a did like 14 of them that day. >> i just want to point one thing out. the only -- you lead with my picture. that was not my -- i have never selfied in my life. >> you don't even know how to do

it. >> let's get to some unusual activity -- or more unusual. >> yeah. >> adt. >> the stock was down about 5%. this is a stock that has a significant amount of short interest, well over 20%. today they started buying the calls. look for this stock to potentially bounce. they paid $1.20 for these. >> still ahead, live from the jp morgan health care conference we've got an interview with the ceo of johnson and johnson on what to expect in 2015. so ally bank really has no hidden fees on savings accounts?

that's right. it's just that i'm worried about you know "hidden things..." ok, why's that? no hidden fees, from the bank where no branches equals great rates.

. let's head back out to the jp morgan health care conference in san francisco. >> as you said we're joined by alex gorsky. thanks so much for joining us. we were talking before we came back from break about the economy and johnson & johnson.

your business stretches across consumer products, pharmaceuticals, medical devices. >> as the world's largest health care company involved in pharmaceuticals, consumers and medical devices, we have a pretty unique purview of what's going on. really the first time some elasticity in demand of health care related to the general economy. prior to that time, health care grew at a pretty consistent rate of 4 or 5 or 6%. what we don't know is there's a lot of enemployed peopunemploye. they weren't insured. we're seeing some of those utilizations such as hospitalizations and primary care physicians come back some, but it still hasn't returned to the prerecession levels.

>> there's more taxes now for you guys. what do you expect to happen with the device tax? >> we have been a support of health care reform from the very beginning, particularly when it comes to getting patients more access. the fact that today we have more than 10 million people likely that have insurance that didn't have it and are getting access to care we think is a great thing. but it's still early days. we know for certain now we're going to have to think about how are we going to ensure that we have not only high quality but also high value healthcare going forward. >> let's talk a little bit about the conference and the big themes you're seeing here. we're in san francisco. we're in this tech hub. we're seeing this convergence of technology and medicine. >> i couldn't think of a better place to have a meeting like this. there's so much great science and research and development

taking place in health care. and having it right here at the north end of silicon valley is really interesting. while we have a lot of challenges there's many reasons to be hopeful about health care. first of all the billions and billions of dollars invested in researchers and investors, many of which are at this conference, we're starting to see the seeds of this pay off. more targeted approaches and therapies for specific conditions is really interesting. bringing other kind of technology such as sensing systems that may be equated with other areas of technology to health care can help us better predict how someone's responding to a particular therapy. and how do we find our way through so much data? what's working, what's not working? what's the genome look like?

being able to culminate all that data to better outcomes is in the best interest of the patient. >> you guys are competitors in a very hot hepatitis c space. >> yes. >> we just saw these deals. an one thing that happened here was it looked like johnson and swr johnson may have got left out in the cold. how are you looking at that? >> we've seen such remarkable progress in a disease like hepatitis c. so many people suffering from this condition that in the past might be on therapies that are about 40% effective and may even have to have a liver transplant later on, and here you have new therapies with 95% cure rates, that's incredible. we're seeing a lot of entrance starting to come in. it's gotten very competitive.

we've seen this dramatic improvement in this efficacy rat rates. we want to come out hard to have the next best therapy and participate in bringing these kind of cures to the market. >> melissa, do you have a question? >> financials and specifically the stronger dollar which has been a headwind for so many multinationals. more than 50% of your revenues come outside the united states. how should we think about this headwind going into 2015? is wall street underestimating what the impact of the stronger dollar could be for a company like yours? >> thank you very much. as you know, we're actually going to be giving our full year 2014 results and fourth quarter 2014 results next week. so all of my responses are predicated on third quarter. but i think that the street is givening to understand what

we're facing in terms of currency head winds. that's europe, also asia. and frankly, the way that we plan for our business, we really try to do it for the long-term. currency is one aspect. we think when we look at some of the new innovations that we're bringing out, that's another issue that we'll continue to deal with. we're confident we can still be successful. >> how should you think about about your m and a strategy? where would you like to at, if anything n your portfolio? >> we're always on the look and on the hunt for areas where we can really make a difference for patients and consumers, where there's unmet medical need, where there's early science, early technology where we can bring our clinical development and turn what may be a very

small product into a very large platform. and at other times we'll actually look for ways to vertically integrate and thing things together. pharmaceuticals we've done a lot of early stage invests and molecules. and we've had extremely good results over the last several years. we've launched 14 compounds since 2009. >> i think that's our time. thank you so much. >> thank you very much and enjoy the conference. it's really great being here. thank you. >> absolutely. >> thank you meg and thank you alex as well. what's your trade in pharmaceuticals? >> i've found other name that is -- names that i like a little bit better now.

merck -- i like those names. i like johnson & johnson, i just want to wait right now for any kind of a pull-back on j and j. >> the rest of the company is going to contract. this is the part where the stock move 2013 from 63 up to 90 bucks. that's where you really find the stock struggling to find the next level higher. >> you wait for them to report on the 20th. this is a company now that's pretty diversified. it's not just medical devices. you could spin these guys off into three companies and have three monster companies. >> still ahead on the program we'll tell you the one oil stock traders are betting will crash. yes, crash, this year. that's next. attention investor! vectorvest mobile is here and it's free! make faster, smarter, better trading decisions with vectorvest mobile.

the most powerful app or managing your portfolio from the palm of your hand. only vectorvest mobile analyzes, ranks and graphs... ...over 16,000 stocks worldwide, everyday,... ...and gives you clear buy, sell, hold recommendations... ...on every stock; anytime, anywhere. vectorvest mobile comes free with your vectorvest trial. get it now! visit vectorvest.com/mobile to get started

. crude got crushed again today and one trader made a bet the oil stocks will continue to take a beating in the coming months. >> so weatherford saw more than

eight times the daily put volume. this is a stock that closed just over $10 today. they were paying just a little over 50 cents for those puts. the stock would have to fall below $6.50 from where it closed today. many of them carry a lot of leverage. that's going to get you right back to those levels and valuations that we were seeing in 2008 and 2009. >> that seems like quite a bet. that's quite a ways down from current levels. >> are they buying it to protect something or are they buying -- >> that's a good point. >> that's the hardest part about the interpretation of that. >> coming up on mad money tonight, kramer has been a fan of pharma since it was at 8

bucks a share. plus, interviews with quarter they are -- stay tuned. do you

like to travel? i'm all about "free" travel, babe. that's what i do. [ female announcer ] fortunately, there's an easier way, with creditcards.com. compare hundreds of cards from every major bank and find the one that's right for you. creditcards.com. it's simple.

. > time now for the final trades. >> i talked about tiffany. i think this is a stock you look at tomorrow and if it trade anywhere near 85, i would be looking that the stock. way over done for one of the quality names in global luxury. >> you've got to watch that national championship game today. 48 million people are going to watch with you. >> we talked about earlier front line. you've got to take a little bit

of money off the table if you want to do it with upside calls. >> pit boss talked about it earlier, jim kramer all the time, look at the move of bmy. bristol meyers my mission is simple, to make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere and i promise to help you find it. "mad money" starts now. >> middle aged men and they have been dying at a far greater rate than they used to. binge drinki